FnCas9 based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV2 variants on a paper strip

Abstract

The COVID-19 pandemic originating in the Wuhan province of China in late 2019 has impacted global health, causing increased mortality among elderly patients and individuals with comorbid conditions. During the passage of the virus through affected populations, it has undergone mutations, some of which have recently been linked with increased viral load and prognostic complexities. Several of these variants are point mutations that are difficult to diagnose using the gold standard quantitative real-time PCR (qRT-PCR) method and necessitates widespread sequencing which is expensive, has long turn-around times, and requires high viral load for calling mutations accurately. Here, we repurpose the high specificity of Francisella novicida Cas9 (FnCas9) to identify mismatches in the target for developing a lateral flow assay that can be successfully adapted for the simultaneous detection of SARS-CoV2 infection as well as for detecting point mutations in the sequence of the virus obtained from patient samples. We report the detection of the S gene mutation N501Y (present across multiple variant lineages of SARS-CoV2) within an hour using lateral flow paper strip chemistry. The results were corroborated using deep sequencing on multiple wild type (n=37) and mutant (n=22) viral RNA samples with a sensitivity of 87% and specificity of 97%. The design principle can be rapidly adapted for other mutations (as shown also for E484K and T716I) highlighting the advantages of quick optimization and roll-out of CRISPR diagnostics (CRISPRDx) for disease surveillance even beyond COVID-19. This study was funded by Council for Scientific and Industrial Research, India.

Data availability

Sequencing data associated with the manuscript have been deposited to GISAID with the following numbers:EPI_ISL_911542, EPI_ISL_911532, EPI_ISL_911543, EPI_ISL_911533, EPI_ISL_911544, EPI_ISL_911534, EPI_ISL_911545, EPI_ISL_911535, EPI_ISL_911546, EPI_ISL_911536, EPI_ISL_911547, EPI_ISL_911537, EPI_ISL_911538, EPI_ISL_911540, EPI_ISL_911541, EPI_ISL_911539 were just released and are now available to all participants in GISAID.

Article and author information

Author details

  1. Manoj Kumar

    in, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0772-1399
  2. Sneha Gulati

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  3. Asgar H Ansari

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  4. Rhythm Phutela

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  5. Sundaram Acharya

    IGIB, CSIR Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    No competing interests declared.
  6. Mohd Azhar

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    Mohd Azhar, Mohd. Azhar is currently an employee of TATA Medical and Diagnostics.
  7. Jayaram Murthy

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  8. Poorti Kathpalia

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  9. Akshay Kanakan

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  10. Ranjeet Maurya

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  11. Janani Srinivasa Vasudevan

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3381-5228
  12. Aparna Murali

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, India
    Competing interests
    No competing interests declared.
  13. Rajesh Pandey

    CSIR Ayurgenomics Unit (TRISUTRA), CSIR Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    No competing interests declared.
  14. Souvik Maiti

    Chemical and Systems Biology, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
    For correspondence
    souvik@igib.res.in
    Competing interests
    No competing interests declared.
  15. Debojyoti Chakraborty

    Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, New Delhi, India
    For correspondence
    debojyoti.chakraborty@igib.in
    Competing interests
    Debojyoti Chakraborty, A patent application has been filed in relation to this work. (0127NF2019)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1460-7594

Funding

University Grants Commission (Graduate student fellowship)

  • Manoj Kumar

IUSSTF (CLP-0033)

  • Rajesh Pandey

CSIR Sickle Cell Anemia Mission (HCP0008)

  • Debojyoti Chakraborty

Tata Steel (SSP 2001)

  • Debojyoti Chakraborty

Lady Tata Young Investigator (GAP0198)

  • Debojyoti Chakraborty

CSIR Sickle Cell Anemia Mission (HCP0008)

  • Souvik Maiti

CSIR (Graduate Student fellowship)

  • Mohd Azhar

CSIR (Graduate Student fellowship)

  • Jayaram Murthy

CSIR (Research Associateship)

  • Sneha Gulati

Indian Council of Medical Research (Graduate Student fellowship)

  • Asgar H Ansari

CSIR (Graduate Student fellowship)

  • Rhythm Phutela

CSIR (Graduate Student fellowship)

  • Sundaram Acharya

CSIR (Research Associateship)

  • Poorti Kathpalia

CSIR (MLP 2005)

  • Rajesh Pandey

Fondation Botnar (CLP-0031)

  • Rajesh Pandey

Intel Corporation (CLP-0034)

  • Rajesh Pandey

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The present study was approved by the Ethics Committee, Institute of Genomics and Integrative Biology, New Delhi (CSIR-IGIB/IHEC/2020-21/01.)

Copyright

© 2021, Kumar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,415
    views
  • 761
    downloads
  • 61
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Manoj Kumar
  2. Sneha Gulati
  3. Asgar H Ansari
  4. Rhythm Phutela
  5. Sundaram Acharya
  6. Mohd Azhar
  7. Jayaram Murthy
  8. Poorti Kathpalia
  9. Akshay Kanakan
  10. Ranjeet Maurya
  11. Janani Srinivasa Vasudevan
  12. Aparna Murali
  13. Rajesh Pandey
  14. Souvik Maiti
  15. Debojyoti Chakraborty
(2021)
FnCas9 based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV2 variants on a paper strip
eLife 10:e67130.
https://doi.org/10.7554/eLife.67130

Share this article

https://doi.org/10.7554/eLife.67130

Further reading

    1. Epidemiology and Global Health
    Yuan Zhang, Dan Tang ... Xing Zhao
    Research Article

    Background:

    Biological aging exhibits heterogeneity across multi-organ systems. However, it remains unclear how is lifestyle associated with overall and organ-specific aging and which factors contribute most in Southwest China.

    Methods:

    This study involved 8396 participants who completed two surveys from the China Multi-Ethnic Cohort (CMEC) study. The healthy lifestyle index (HLI) was developed using five lifestyle factors: smoking, alcohol, diet, exercise, and sleep. The comprehensive and organ-specific biological ages (BAs) were calculated using the Klemera–Doubal method based on longitudinal clinical laboratory measurements, and validation were conducted to select BA reflecting related diseases. Fixed effects model was used to examine the associations between HLI or its components and the acceleration of validated BAs. We further evaluated the relative contribution of lifestyle components to comprehension and organ systems BAs using quantile G-computation.

    Results:

    About two-thirds of participants changed HLI scores between surveys. After validation, three organ-specific BAs (the cardiopulmonary, metabolic, and liver BAs) were identified as reflective of specific diseases and included in further analyses with the comprehensive BA. The health alterations in HLI showed a protective association with the acceleration of all BAs, with a mean shift of –0.19 (95% CI −0.34, –0.03) in the comprehensive BA acceleration. Diet and smoking were the major contributors to overall negative associations of five lifestyle factors, with the comprehensive BA and metabolic BA accounting for 24% and 55% respectively.

    Conclusions:

    Healthy lifestyle changes were inversely related to comprehensive and organ-specific biological aging in Southwest China, with diet and smoking contributing most to comprehensive and metabolic BA separately. Our findings highlight the potential of lifestyle interventions to decelerate aging and identify intervention targets to limit organ-specific aging in less-developed regions.

    Funding:

    This work was primarily supported by the National Natural Science Foundation of China (Grant No. 82273740) and Sichuan Science and Technology Program (Natural Science Foundation of Sichuan Province, Grant No. 2024NSFSC0552). The CMEC study was funded by the National Key Research and Development Program of China (Grant No. 2017YFC0907305, 2017YFC0907300). The sponsors had no role in the design, analysis, interpretation, or writing of this article.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Bo Zheng, Bronner P Gonçalves ... Caoyi Xue
    Research Article

    Background:

    In many settings, a large fraction of the population has both been vaccinated against and infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection.

    Methods:

    We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April–May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHRs).

    Results:

    275,896 individuals were diagnosed with real-time polymerase chain reaction-confirmed SARS-CoV-2 infection in April–May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% confidence interval 0.79–0.85). For patients who had received one, two, or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76–0.93), 0.87 (0.83–0.90), and 0.96 (0.74–1.23), respectively. Post-infection vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44–0.58) and 0.67 (0.61–0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective.

    Conclusions:

    In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries.

    Funding:

    This study was funded the Key Discipline Program of Pudong New Area Health System (PWZxk2022-25), the Development and Application of Intelligent Epidemic Surveillance and AI Analysis System (21002411400), the Shanghai Public Health System Construction (GWVI-11.2-XD08), the Shanghai Health Commission Key Disciplines (GWVI-11.1-02), the Shanghai Health Commission Clinical Research Program (20214Y0020), the Shanghai Natural Science Foundation (22ZR1414600), and the Shanghai Young Health Talents Program (2022YQ076).